Aptose Biosciences' Shares Tumble Ahead of Nasdaq Delisting

Dow Jones

04-01

纳斯达克-5.82%

By Katherine Hamilton

Shares of Aptose Biosciences fell after the company said it was being delisted from Nasdaq.

The stock dropped 41% to $1.87 on Tuesday, at one point hitting a 52-week low of $1.35. Shares have lost two-thirds of their value since the start of the year.

The cancer-treatment developer said Tuesday the Nasdaq Hearings Panel made the determination to delist the company starting on Wednesday.

Aptose was unable to comply with the Nasdaq's equity requirement by the end of March, it said.

The company plans to review all available options, including an appeal of Nasdaq's decision. It will continue to execute its business plan and seek listing on a U.S. national securities exchange, it said. Aptose's shares are still listed on TSX under the symbol APS.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

April 01, 2025 15:15 ET (19:15 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

no data

没有相关数据

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2524125920"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2524125920\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2524125920?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-02 03:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2524125920","market":"fut","top_or_hot":-1,"title":"Aptose Biosciences' Shares Tumble Ahead of Nasdaq Delisting","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<p>\n  Shares of Aptose Biosciences fell after the company said it was being delisted from Nasdaq. \n</p>\n<p>\n  The stock dropped 41% to $1.87 on Tuesday, at one point hitting a 52-week low of $1.35. Shares have lost two-thirds of their value since the start of the year. \n</p>\n<p>\n  The cancer-treatment developer said Tuesday the Nasdaq Hearings Panel made the determination to delist the company starting on Wednesday. \n</p>\n<p>\n  Aptose was unable to comply with the Nasdaq's equity requirement by the end of March, it said. \n</p>\n<p>\n  The company plans to review all available options, including an appeal of Nasdaq's decision. It will continue to execute its business plan and seek listing on a U.S. national securities exchange, it said. Aptose's shares are still listed on TSX under the symbol APS. \n</p>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 01, 2025 15:15 ET (19:15 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aptose Biosciences' Shares Tumble Ahead of Nasdaq Delisting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAptose Biosciences' Shares Tumble Ahead of Nasdaq Delisting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-04-02 03:15</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<p>\n  Shares of Aptose Biosciences fell after the company said it was being delisted from Nasdaq. \n</p>\n<p>\n  The stock dropped 41% to $1.87 on Tuesday, at one point hitting a 52-week low of $1.35. Shares have lost two-thirds of their value since the start of the year. \n</p>\n<p>\n  The cancer-treatment developer said Tuesday the Nasdaq Hearings Panel made the determination to delist the company starting on Wednesday. \n</p>\n<p>\n  Aptose was unable to comply with the Nasdaq's equity requirement by the end of March, it said. \n</p>\n<p>\n  The company plans to review all available options, including an appeal of Nasdaq's decision. It will continue to execute its business plan and seek listing on a U.S. national securities exchange, it said. Aptose's shares are still listed on TSX under the symbol APS. \n</p>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 01, 2025 15:15 ET (19:15 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2524125920","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2524125920","pubTimestamp":1743534900,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Aptose Biosciences fell after the company said it was being delisted from Nasdaq.The stock dropped 41% to $1.87 on Tuesday, at one point hitting a 52-week low of $1.35. Shares have lost two-thirds of their value since the start of the year.The cancer-treatment developer said Tuesday the Nasdaq Hearings Panel made the determination to delist the company starting on Wednesday.Aptose was unable to comply with the Nasdaq's equity requirement by the end of March, it said.The company plans to review all available options, including an appeal of Nasdaq's decision. It will continue to execute its business plan and seek listing on a U.S. national securities exchange, it said. Aptose's shares are still listed on TSX under the symbol APS.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Aptose Biosciences股价在纳斯达克退市前暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{".IXIC":1,"APTO":1,"APTOF":1,"MNQmain":0.6,"NQmain":1,"NDAQ":1,"NVIW.SI":0.6,"PSQ":0.6,"QID":0.6,"QLD":0.6,"SQQQ":0.6,"TQQQ":0.6,"TSYW.SI":0.6,"USAW.SI":0.6,"USJW.SI":0.6},"content_text":"By Katherine Hamilton \n\n\n  Shares of Aptose Biosciences fell after the company said it was being delisted from Nasdaq. \n\n\n  The stock dropped 41% to $1.87 on Tuesday, at one point hitting a 52-week low of $1.35. Shares have lost two-thirds of their value since the start of the year. \n\n\n  The cancer-treatment developer said Tuesday the Nasdaq Hearings Panel made the determination to delist the company starting on Wednesday. \n\n\n  Aptose was unable to comply with the Nasdaq's equity requirement by the end of March, it said. \n\n\n  The company plans to review all available options, including an appeal of Nasdaq's decision. It will continue to execute its business plan and seek listing on a U.S. national securities exchange, it said. Aptose's shares are still listed on TSX under the symbol APS. \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 01, 2025 15:15 ET (19:15 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0}}}

如果下载按钮点击无跳转，请点击右上角菜单选择 “在浏览器打开”

立即咨询
下载APP
扫码下载APP